Acrivastine, terfenadine and diphenhydramine effects on driving performance as a function of dose and time after dosing.
about
Repeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performanceExtended driving impairs nocturnal driving performances.Non-cardiac adverse effects of antihistamines (H1-receptor antagonists).Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects.Residual effects of zopiclone 7.5 mg on highway driving performance in insomnia patients and healthy controls: a placebo controlled crossover study.On-the-road driving performance and driving-related skills in older untreated insomnia patients and chronic users of hypnotics.Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers.In-car nocturnal blue light exposure improves motorway driving: a randomized controlled trialSedation and antihistamines: a review of inter-drug differences using proportional impairment ratios.Comparison of intranasal corticosteroids and antihistamines in allergic rhinitis: a review of randomized, controlled trials.Comparing treatment effects of oral THC on simulated and on-the-road driving performance: testing the validity of driving simulator drug researchEffects of stimulant drugs on actual and simulated driving: perspectives from four experimental studies conducted as part of the DRUID research consortiumThe interactive effects of extended wakefulness and low-dose alcohol on simulated driving and vigilance.Aging and nocturnal driving: better with coffee or a nap? A randomized study.Histamine H1 receptor blockade predominantly impairs sensory processes in human sensorimotor performance.What to do with refractory urticaria patients.Effects of central nervous system drugs on driving: speed variability versus standard deviation of lateral position as outcome measure of the on-the-road driving test.Next-day residual effects of gabapentin, diphenhydramine, and triazolam on simulated driving performance in healthy volunteers: a phase 3, randomized, double-blind, placebo-controlled, crossover trial.Effects of alcohol on automated and controlled driving performances.Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989-94.Slow eyelid closure as a measure of driver drowsiness and its relationship to performance.Can the MSLT be a useful tool to assess motor vehicle crash risk in sleepy drivers?Effects of emedastine and cetirizine, alone and with alcohol, on actual driving of males and females.A combined neurophysiological and behavioural study into the stimulating effects of fexofenadine on performance.Histamine H1-receptor blockade in humans affects psychomotor performance but not memory.The role of P-glycoprotein in CNS antihistamine effects.Maintenance of Wakefulness Test, obstructive sleep apnea syndrome, and driving risk.Marijuana, alcohol and actual driving performance.Evaluating the effects of bilingual traffic signs on driver performance and safety.Development of terfenadine-pseudoephedrine double-layer tablet dissolution-equivalent to core tablet.
P2860
Q28289605-87BB1FE7-C7D7-4935-A0A2-D056F6470C5EQ33378468-603A0C9A-1A52-40DA-9C70-7A22444BFAECQ33709789-5ED32C0D-57AB-48D3-BF4F-ACBA342CC729Q33709795-F4D291A5-0D70-4B6D-8840-84D29E06B8B0Q33810623-E38E2425-A9FF-444B-BA00-443C8674ADBFQ33810643-7A942D2C-5093-43A3-A080-4A83F974C5E7Q34139004-D97C5240-962F-4BA8-A2D5-A1F1E84F4B64Q34456232-5CB12D5C-EDFE-411E-A700-351D77316B9AQ34982550-2074C990-1F8C-4A03-8123-FB9B1BD239D0Q35627751-26D177E3-4FC2-42AC-A217-5252695AD6BCQ35884188-D28ECB13-6221-4433-9B9D-28DF1E2B957BQ36091036-59EC4CDD-0AE6-4A35-8CBD-BC37EC74B39BQ36493193-1D0127A5-1E13-49B8-A05C-40C0A0E242EAQ36511605-850A5AC5-9D6C-4CED-9D49-021B316EFC5AQ37230876-57AB1476-FC90-4309-AC57-3A9E464362F5Q37856874-7CC1ED65-2BEB-45E7-9B88-3C773065E467Q38174544-E8F391C9-B140-4CE6-B213-9723206752D5Q39886402-37629ED0-E537-4F13-851F-E01B24161000Q40154364-2877E8D9-258D-4747-86B8-7599D5208705Q40483823-AB0EE8A3-23A9-45BA-BAB7-03E03AAABCBDQ40845437-3344AD9E-1BE5-48CF-AE1F-F265BEE5F767Q40914207-19F4E45C-601A-4478-8235-72A895F28A0AQ43956688-9CC12270-8353-434A-B75B-22674691D6DFQ46713303-82351FD1-4A61-41A3-A051-8E8C5AEACC7AQ46798714-E5D9CCB3-F20A-412C-93EE-8B7D444DDE63Q48093193-01D5B959-B622-4C05-8D4A-F71649950CF4Q48427182-C252DE96-A869-42A0-9EB0-470F1858BCB8Q48458471-EAD3410B-213B-4885-B499-C19CE8BBAEBDQ52856889-80231212-2E9E-49A4-8EEC-9B426C24F339Q53943851-3D12B7D0-D5DD-406C-A0DC-EF6D8F199058
P2860
Acrivastine, terfenadine and diphenhydramine effects on driving performance as a function of dose and time after dosing.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Acrivastine, terfenadine and d ...... of dose and time after dosing.
@en
Acrivastine, terfenadine and d ...... of dose and time after dosing.
@nl
type
label
Acrivastine, terfenadine and d ...... of dose and time after dosing.
@en
Acrivastine, terfenadine and d ...... of dose and time after dosing.
@nl
prefLabel
Acrivastine, terfenadine and d ...... of dose and time after dosing.
@en
Acrivastine, terfenadine and d ...... of dose and time after dosing.
@nl
P356
P1476
Acrivastine, terfenadine and d ...... of dose and time after dosing.
@en
P2093
J F O'Hanlon
J G Ramaekers
P2888
P304
P356
10.1007/BF02570506
P577
1994-01-01T00:00:00Z